HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife's 10.3% Slump Tracks With Full-Year Guidance But Light Seen At The End Of 2022

Executive Summary

Herbalife reported a double digit decrease in net sales during its second quarter, following similar results in the first quarter. The direct seller also plans to launch its digital platform Herbalife One to connect distributers and consumers and promote sales.

You may also be interested in...



Herbalife Relaunches To ‘2.0’ With 'Unified, Global Platform' After Sales Fall 10.3% In 2022

Direct seller announces relaunch after year-long sales slump blamed on macroeconomic inflationary pressures. No full-year guidance due to rapidly shifting macroeconomic environment and increased market volatility.

P&G Recalibrates ‘Irresistible Superiority’ As Economy, Competition Tighten

Procter & Gamble R&D aims to answer demand for "instant gratification" while the firm works to educate consumers on proper use of products for better experiences and improved brand loyalty, among other tactics discussed in its 17 November Investor Day presentation. 

Herbalife Returns To Its History For Leadership Through Current ‘Challenging Landscape’

Herbalife announced Michael Johnson as chairman and interim CEO, replacing John Agwunobi, about 90 minutes before it announced a 9.5% decrease in Q3 net sales to $1.3bn. Its reported net income was $82.2m, down nearly 21%.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel